

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/926,123	09/06/2001	Hiroaki Nakagami	213445US0PCT	6130
22850 75	11/05/2002			
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC			EXAMINER	
FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY			PULLIAM, AMY E	
AKLINGTON,	ARLINGTON, VA 22202		ART UNIT	PAPER NUMBER
			1615	<u> </u>
			DATE MAILED: 11/05/2002	e C

Please find below and/or attached an Office communication concerning this application or proceeding.

	,	Application No.	Applicant(s)			
Office Action Summary		09/926,123	NAKAGAMI ET AL.			
		Examiner	Art Unit			
		Amy E Pulliam	1615			
	The MAILING DATE of this communication appears on the cov r sheet with the correspondence address Period for Reply					
THE I - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be tin by within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	nely filed rs will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
1)⊠	Responsive to communication(s) filed on 06	September 2001 .				
2a)□	This action is FINAL. 2b)⊠ Th	nis action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠	Claim(s) <u>1-20</u> is/are pending in the application	٦.				
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>1-20</u> is/are rejected.					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)□ Some * c)□ None of:						
	1. Certified copies of the priority document	s have been received.				
	2. Certified copies of the priority document	s have been received in Applicati	on No			
3.☑ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
) \square The translation of the foreign language proacknowledgment is made of a claim for domest					
Attachment	t(s)					
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>5</u>	5) Notice of Informal I	/ (PTO-413) Paper No(s) Patent Application (PTO-152)			
J.S. Patent and Tr PTO-326 (Re	•	ction Summary	Part of Paper No. 6			

Application/Control Number: 09/926,123

Art Unit: 1615

DETAILED ACTION

Receipt of Papers

Receipt is acknowledged of the Priority Papers, the Preliminary Amendment A, and the Information Disclosure Statement, received by the Office September 6, 2001, November 1, 2001, and December 7, 2001

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-10, 14-16, and 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 93/17667 Yajima *et al.* Yajima *et al.* disclose a composition for oral preparation, which comprises a complex formed by dispersing or dissolving an unpleasantly tasting drug and a polymer in a substance having a low melting point, and a sugar alcohol (abstract). Yajima *et al.* teach that the composition is excellent in masking unpleasantly tasting drugs and has excellent performance in biological use. More specifically, Yajima *et al.* teach that the unpleasantly tasting drug can be erythromycin, or clarithromycin, among others (page 4, paragraph 2). Yajima *et al.* teach that the substance having a low melting point if a water-insoluble or water sparingly soluble substance with a melting point of 40 to 120 degrees Celsius (page 4, paragraph 5), for example, hydrogenated oil, stearyl alcohol, glycerin fatty acid ester (page 5, paragraph 1). Yajima *et al.* also teach that the sugar alcohol includes sorbitol, xylitol, and maltitol (page 5,

Application/Control Number: 09/926,123

Art Unit: 1615

paragraph 3), and that it is present at between 10 and 70 % by weight (page 5, paragraph 4). Yajima *et al.* also teaches the process of granulation through spray drying (see examples 1-13). Lastly, Yajima *et al.* teaches the composition as a dosage form for oral preparations. Therefore, the teachings of Yajima *et al.* anticipate applicant's instant claims.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 11-13 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yajima et al.

Yajima *et al.* are discussed above as teaching a composition for oral preparation which comprises a unpleasantly tasting drug, a substance with a low melting point, and a sugar alcohol.

· Yajima et al. do not specifically teach each and every one of applicant's claimed active agents. However, Yajima et al. does teach some of the actives claimed by applicant. It is the position of the examiner that one of ordinary skill in the art would have been motivated to use any active which is known to have an unpleasant taste, in a formulation whose sole purpose is to mask the unpleasant taste of the active agent. The expected result would be a dosage form without an unpleasant taste.

Additionally, Yajima et al. do not teach the specific particle size of the granulated product. It is the position of the examiner that one of ordinary skill in the art would have been

Art Unit: 1615

motivated to create a granulated product, with taste masking capabilities, regardless of the particular particle size, based on the teachings of Yajima et al. The reference clearly teaches the process of granulation (See examples 1-13), and absent a clear showing of criticality, the determination of the particular particle size is within the skill of the ordinary worker as part of the process of normal optimization. The expected result would be a successful granulated dosage form with taste masking capabilities.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E Pulliam whose telephone number is 703-308-4710. The examiner can normally be reached on Mon-Thurs 7:30-5:00, Alternate Fri 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3592 for regular communications and 703-305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

A. Pulliam **Patent Examiner** Art Unit 1615 November 4, 2002

TECHNOLOGY CENTER 1600